{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T13:21:12Z","timestamp":1788355272487,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"DOI":"10.1007\/s11739-026-04510-y","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:59:58Z","timestamp":1788353998000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Refractory lupus nephritis: national multicenter study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9654-0698","authenticated-orcid":false,"given":"Vanesa","family":"Calvo-R\u00edo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Gonz\u00e1lez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pa\u00fal","family":"Hern\u00e1ndez Velasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Morales Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Ugena-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Margaret","family":"Riveros Frutos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Belzunegui Otano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahy Mar\u00eda","family":"Brandy Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngel","family":"Garc\u00eda Manzanares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Ram\u00f3n","family":"Lama Riazuelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josefina","family":"Cort\u00e9s-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irati","family":"Urionag\u00fcena Onaindia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"G\u00f3mez Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabela","family":"Fern\u00e1ndez Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Corteguera Coro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Josu\u00e9","family":"Fari\u00f1a Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"\u00c1lvarez del Buergo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"Lorenzo Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Carri\u00f3n Barber\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Mart\u00edn Penagos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"issue":"1","key":"4510_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41572-019-0141-9","volume":"6","author":"HJ Anders","year":"2020","unstructured":"Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C (2020) Lupus nephritis. Nat Rev Dis Primers 6(1):7","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"4510_CR2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/acr.21664","volume":"64","author":"BH Hahn","year":"2012","unstructured":"Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64(6):797\u2013808","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"2","key":"4510_CR3","first-page":"332","volume":"34","author":"L Christopher-Stine","year":"2007","unstructured":"Christopher-Stine L, Siedner M, Lin J et al (2007) Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 34(2):332\u2013335","journal-title":"J Rheumatol"},{"issue":"4","key":"4510_CR4","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/rheumatology\/keaa491","volume":"60","author":"E Gisca","year":"2021","unstructured":"Gisca E, Duarte L, Farinha F, Isenberg DA (2021) Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology (Oxford) 60(4):1814\u20131822","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"4510_CR5","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/art.39594","volume":"68","author":"MG Tektonidou","year":"1971","unstructured":"Tektonidou MG, Dasgupta A, Ward MM (1971) Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68(6):1432\u20131441","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"4510_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.2215\/CJN.05780616","volume":"12","author":"S Almaani","year":"2017","unstructured":"Almaani S, Meara A, Rovin BH (2017) Update on lupus nephritis. Clin J Am Soc Nephrol 12(5):825\u2013835","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4510_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1191\/0961203305lu2057oa","volume":"14","author":"CC Mok","year":"2005","unstructured":"Mok CC (2005) Prognostic factors in lupus nephritis. Lupus 14(1):39\u201344","journal-title":"Lupus"},{"key":"4510_CR8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128","journal-title":"N Engl J Med"},{"issue":"1","key":"4510_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2025-001825","volume":"13","author":"P Vidal-Montal","year":"2026","unstructured":"Vidal-Montal P, Fabregat A, Altab\u00e1s-Gonz\u00e1lez I et al (2026) Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry. Lupus Sci Med 13(1):e001825","journal-title":"Lupus Sci Med"},{"key":"4510_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2021.102729","volume":"124","author":"M Gatto","year":"2021","unstructured":"Gatto M, Saccon F, Zen M et al (2021) Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN): results from a large, nationwide, multicentric cohort. J Autoimmun 124:102729","journal-title":"J Autoimmun"},{"key":"4510_CR11","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne D, Tummala R, Bekker P et al (2022) Phase II randomized trial of anifrolumab in active lupus nephritis. Ann Rheum Dis 81:496\u2013506","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"4510_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.4492","volume":"5","author":"Z Zheng","year":"2022","unstructured":"Zheng Z, Zhang W, Zhang J et al (2022) Tacrolimus versus intravenous cyclophosphamide for induction therapy in lupus nephritis: randomized clinical trial. JAMA Netw Open 5(3):e221234","journal-title":"JAMA Netw Open"},{"issue":"1","key":"4510_CR13","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill JT, Neuwelt CM, Wallace DJ et al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62(1):222\u2013233. https:\/\/doi.org\/10.1002\/art.27233","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4510_CR14","first-page":"205","volume":"5","author":"F Alshaiki","year":"2018","unstructured":"Alshaiki F, El-Sabawi B, Baghdadi L et al (2018) Outcomes of rituximab therapy in refractory lupus: a meta-analysis. Eur J Rheumatol 5(4):205\u2013211","journal-title":"Eur J Rheumatol"},{"key":"4510_CR15","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1016\/S0140-6736(21)00578-X","volume":"397","author":"BH Rovin","year":"2021","unstructured":"Rovin BH, Teng YKO, Ginzler EM et al (2021) Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397:2070\u20132080","journal-title":"Lancet"},{"key":"4510_CR16","unstructured":"Furie RA, Aroca G, Cascino MD, et al (2025) Obinutuzumab for proliferative lupus nephritis (REGENCY): a randomised, double-blind, placebo-controlled phase 3 trial. N Engl J Med"},{"issue":"5","key":"4510_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1053\/j.ackd.2019.08.007","volume":"26","author":"T Wong","year":"2019","unstructured":"Wong T, Goral S (2019) Lupus nephritis and kidney transplantation: where are we today? Adv Chronic Kidney Dis 26(5):313\u2013322","journal-title":"Adv Chronic Kidney Dis"},{"issue":"1","key":"4510_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.nefroe.2023.05.006","volume":"43","author":"JE Rojas-Rivera","year":"2023","unstructured":"Rojas-Rivera JE, Garc\u00eda-Carro C, \u00c1vila AI et al (2023) Consensus document of the Spanish Group for the Study of the Glomerular Diseases (GLOSEN) for the diagnosis and treatment of lupus nephritis. Nefrolog\u00eda (English Edition) 43(1):6\u201347","journal-title":"Nefrolog\u00eda (English Edition)"},{"issue":"9","key":"4510_CR19","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M, Costenbader K, Daikh D et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 71(9):1400\u20131412","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"4510_CR20","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Orbai AM, Alarc\u00f3n GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677\u20132686","journal-title":"Arthritis Rheum"},{"issue":"9","key":"4510_CR21","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/art.1780400928","volume":"40","author":"MC Hochberg","year":"1997","unstructured":"Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725","journal-title":"Arthritis Rheum"},{"issue":"4","key":"4510_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.kint.2017.11.023","volume":"93","author":"IM Bajema","year":"2018","unstructured":"Bajema IM, Wilhelmus S, Alpers CE et al (2018) Revision of the International Society of Nephrology\/Renal Pathology Society classification for lupus nephritis: clarification of definitions and modified National Institutes of Health activity and chronicity indices. Kidney Int 93(4):789\u2013796","journal-title":"Kidney Int"},{"issue":"9","key":"4510_CR23","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1136\/annrheumdis-2017-212732","volume":"77","author":"G Moroni","year":"2018","unstructured":"Moroni G, Vercelloni PG, Quaglini S et al (2018) Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis 77(9):1318\u20131325","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"4510_CR24","doi-asserted-by":"publisher","first-page":"2319","DOI":"10.1007\/s00296-023-05389-0","volume":"43","author":"E Calatayud","year":"2023","unstructured":"Calatayud E, Montomoli M, \u00c1vila AI, Sancho Calabuig A, Alegre-Sancho JJ (2023) Experience with abatacept in refractory lupus nephritis. Rheumatol Int 43(12):2319\u20132326","journal-title":"Rheumatol Int"},{"issue":"9","key":"4510_CR25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41584-021-00668-1","volume":"17","author":"MRW Barber","year":"2021","unstructured":"Barber MRW, Drenkard C, Falasinnu T et al (2021) Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol 17(9):515\u2013532","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"4510_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2022-000773","volume":"9","author":"H Luo","year":"2022","unstructured":"Luo H, Zhou Y, Chen G et al (2022) Response to therapy at 6 months predicts long-term renal outcome in lupus nephritis with poor kidney function. Lupus Sci Med 9(1):e000773","journal-title":"Lupus Sci Med"},{"issue":"1","key":"4510_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000584","volume":"9","author":"S McDonald","year":"2022","unstructured":"McDonald S, Yiu S, Su L et al (2022) Predictors of treatment response in a lupus nephritis population: lessons from the Aspreva Lupus Management Study (ALMS) trial. Lupus Sci Med 9(1):e000584","journal-title":"Lupus Sci Med"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-026-04510-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-026-04510-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T12:59:59Z","timestamp":1788353999000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-026-04510-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":27,"alternative-id":["4510"],"URL":"https:\/\/doi.org\/10.1007\/s11739-026-04510-y","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"value":"1828-0447","type":"print"},{"value":"1970-9366","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following financial interests\/personal relationships which may be considered as potential competing interests: Vanesa Calvo-Rio reports a relationship with AstraZeneca, that includes: speaking and lecture fees and travel reimbursement. Vanesa Calvo-Rio reports a relationship with GSK that includes: speaking and lecture fees and travel reimbursement. Ricardo Blanco reports a relationship with AstraZeneca that includes: speaking and lecture fees. Ricardo Blanco reports a relationship with GSK that includes: speaking and lecture fees and travel reimbursement. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The following authors declare that they have no known competing financial interests or personal disclosures: Celia Gonz\u00e1lez-Garc\u00eda, Pa\u00fal Hern\u00e1ndez Velasco, Enrique Morales Ruiz, Raquel Ugena-Garc\u00eda, Anne Margaret Riveros Frutos, Joaqu\u00edn Belzunegui Otano, Anahy Mar\u00eda Brandy Garc\u00eda, \u00c1ngel Garc\u00eda Manzanares, Jose Ram\u00f3n Lama Riazuelo, Sebasti\u00e1n Sandoval, Josefina Cort\u00e9s-Hern\u00e1ndez, Irati Urionag\u00fcena Onaindia, Susana G\u00f3mez Castro, Sabela Fern\u00e1ndez Aguado, Montserrat Corteguera Coro, Aaron Josu\u00e9 Fari\u00f1a Gonzalez, Mar\u00eda \u00c1lvarez del Buergo, Andr\u00e9s Lorenzo Mart\u00edn, Irene Carri\u00f3n Barber\u00e1, Luis Mart\u00edn Penagos.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}